Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISPR_SCD001 in Severe Sickle Cell Disease
NCT04774536Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Mar 2030
- Modality
- Gene Silencing, CRISPR-Cas9, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CRISPR_SCD001 in sickle cell disease (SCD). Started Aug 2025; status: recruiting.
02
Drugs
CRISPR_SCD001
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04774536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774536.